Finch Therapeutics Group Inc
FNCH
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.04M
Close$
$-10.92
225.5% downside
Current Fair Value
225.5% downsideOvervalued by 225.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.04 Million |
|---|---|
| Enterprise Value | $25.00 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.64 |
| Beta | 1.17 |
| Outstanding Shares | 1,605,763 |
Return
| Return on Equity | -99.63% |
|---|---|
| Return on Assets | -31.08% |
| Return on Invested Capital | -48.13% |
Valuation & Multiples
| P/E Ratio | -0.87 |
|---|---|
| PEG | 2.85 |
| Price to Sales | 8.7 |
| Price to Book Ratio | 1.09 |
| Enterprise Value to Revenue | 8.79 |
| Enterprise Value to EBIT | -1.26 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.16 |
| Debt to Equity | 2.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 27, 2026
EPS Estimate
$-30.00
Average shareholder expectationRevenue Estimate
$3.60 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Finch Therapeutics Group Inc
131 employeesFinch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and ta...